Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
lidocaine (lidocaine hydrochloride), epinephrine
Liqvor CJSC
N01BB52
lidocaine (lidocaine hydrochloride), epinephrine
10mg/ml+ 0,01mg/ml
solution for injection
(1) and (10) glass vial 20ml
Prescription
Registered
2018-07-11
INSTRUCTIONS FOR MEDICAL USE LIDOCAINE-LIQVO WITH EPINEPHRINE 1 % and 2 % solution for injection TRADE NAME: Lidocaine-Liqvo with epinephrine INTERNATIONAL NONPROPRIETARY NAME: Lidocaine, Epinephrine. PHARMACEUTICAL FORM: Solution for injection. STRENGTH: 1 % and 2 % with epinephrine 1:100000 COMPOSITION: _ active ingredients_: lidocaine hydrochloride – 10.0 mg or 20.0 mg, epinephrine hydrotartrate equivalent to epinephrine – 0.01 mg; _inactive ingredients_: sodium chloride – 7.0 mg, sodium metabisulfite – 0.5 mg, citric acid – 0.2 mg, benzalkonium chloride – 0.05 mg, water for injection – up to 1.0 ml. DESCRIPTION: Clear, colorless or slightly yellowish solution. PHARMACOTHERAPEUTICAL GROUP: Local anesthetic. CODE ATC: N01BB52 PHARMACOLOGICAL EFFECT _PHARMACODYNAMICS _ Lidocaine is a local anaesthetic of the amide type. It causes all types of local anesthesia: terminal, infiltration, conduction. The local anesthetic action consists in neuronal membrane stabilization by reducing its penetration for sodium ions, which prevents action potential occurrence and impulse conduction. It rapidly hydrolyzes in a slightly alkaline media of tissues and after a short latent period acts within 60-90 minutes. Anesthetic activity decreases with tissue acidosis. Epinephrine - adrenoceptor agonist, constricts blood vessels and prolongs lidocaine action. _PHARMACOKINETICS _ Lidocaine is readily absorbed from the gastrointestinal tract, from mucous membranes and through damaged skin also in case of intramuscular administration. The elimination half-life is 2 hours. Lidocaine is metabolized in liver with formation of two pharmacologically active metabolites. It_ _ eliminates with urine: approximately 90% of dose is excreted in the form of metabolites and less than 10% - unchanged. Lidocaine crosses the blood-brain and placental barriers. _ _ _ _ INDICATIONS FOR USE All types of local anesthesia (infiltration and conduction anesthesia, peripheral nerve blocks) in dentistry, ophthalmology, otorhinolaryngology, obstetrics Read the complete document
CYM.I$ APHA fr XAFAKTNFI.{.C T}.I KA fi A KAPCT:BAHI{ O I- O . : : . : . NPHIIAPAT'A JIHIIOKAI{I{-fl14KBO c slrI{He{rpr'rnou p A c"rB0 p fl .rln lt rrr, er rcqHil I. Konrmepqecgoe Hatr1r,rerronRnire Hp€,lrftpnra: -llmgclxalrul-Jl.Hmuo c SIlt{ttetfpr'tHoir,t Mexgynapognoe rdar{M€HoBaHrre t}IirIIBIIsro BeIIIecTBa; JlLtlIoKaHH. J[ r"tAo xitl.t FI a r]"Ir:tp oxJlolltlJt 3 ni,rnedlp pi ir fr rl,lgpol:ap ar (n ilepecrlere Ha rnnne$pr.tn) Bcno.'ttoza m €..it bt-t d e ge u{e( tn6fr ; FIarpr'u xitopl'Iit Harpr'tn u era6ltcytn r'$llr Kltc;lttl'ra;r,ltH,:tlllueu :: : E exsalxonl.Tfl xiropl,Ir B ojla riu{ I'Ir-I"l;ercuutl 3. @apncauerTll,Hecliafi rpapma: paetnop finx I :100000 : 4. Kn HHI{(IecKIIe xa pa K r e p l t c r l { K H 4,1 flara3aullff K npltmeilenlllo Ilce eggbr [4ecrHofr aHscr:e3r,tn (lrnfturrurpirqnonFlfl$, npono.{FlldKoBflfi al{ecre3l4s} 6lorajta ilepFr$epuuecnlrx , r{epBors) n cloturaroilorl{Fl, odir:aur,turoror}lr{. o.ropFi-IoJrapr"tHr'ojlor"r.i4. aKyr.rJellcTBe, Il{FIeKOJtO[rdl4. Xl,Ipypr]lt{- JIepMA'r0,rlol"{1'1. I rnrane.clpHH. 2, Ksnn*recr*e*Huft u **,-il***ennnrfi oo*** .u$rtt fl it ; t d'r€fffd $6' 'LP/8 il, ffi;*-"' ""r vY+! ws f io r, r-'i il i, ii { r,; !Jb4,'r,/ ad f { 10.0:Lrr I'lnll 20,0 ur - 0 , 0 1 i v l r 7"0 ir,tr : - 0oS n$r , ,, - 0o? ntr ' -0,05 nrr : - Ao I rln. ,*iur,**Hlu,lT- I X u 2"/o c 3lr l'lHe$pnnom B:pgc.llt rM Fr Ae1rr\{ c'rapilte l2 .i.re"r ilorra3auo ilpt"t\tsltenl'le lu/o tt 2 % pacrl}oiloB JtLtJloKtl{I1t[; jlerriM [] It03pa,f're crttl]iile .l lo.na {to t? ,rler 7o/r, pacrBCIpa 4.2. Cnoco6 np'MerreH'n [r Ao3l,r r*,ii i" i: ig!c{I/p6' il {' At}f€" l*err*oro rnu'*t,ur. ii i'Il-'iiit; iiir'l ' /16 %a ;/ ! : n i " " ; r i i Pexpl;vt.q03tlpoBar-tptfi )'c'rarJilBilttBilloT r.rFrllHBI,TiIyarbll,o" B 3i1B!ICIdN'lOCT'I'I OT nona3ar{nir. nrutlri.FttscKoii u"r.:r'r,au}.rr{ pr r{ciloJlbs),eur:tYt $erapcrneituofi $optutur. liperrapnl cJreJweir BBo;1l,t'lr, Me.ilitelrr,Io. B rI[tFrN'l€ll.blUeilt ttoHHefflip{}l{l{l'I r{ Har.ri\,rer{bmepi jlo3e. ,lrarogeu 'rpe6yeirtr,Il:i rclrQexr. I Read the complete document